Yanagisawa T, Hata K, Narita S, Hatakeyama S, et al. Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy. Prostate 2023 Jan 20. doi: 10.1002/pros.24488.
PMID: 36661102